Company News
Travere FDA Approves FILSPARI, Shares Jump 44%
Travere Therapeutics shares jumped 44% after FDA approved FILSPARI for focal segmental glomerulosclerosis (FSGS).
FILSPARI is the first FDA‑approved therapy for FSGS, expanding its label from IgA neph
